Jeff Field Joins Clear Labs as Chief Commercial Officer

Share Article

Healthcare industry veteran with deep experience in NGS will lead development and scaling of Clear Labs’ signature products, Clear Safety and Clear Dx

An experienced operator in the NGS and diagnostics industry, Field will oversee the ongoing commercialization of Clear Safety and Clear Dx nationally and internationally, including the marketing and sale of both products to partners in food safety and in healthcare.

Clear Labs, provider of the only automated and intelligent diagnostic NGS platform, today announced the hire of Jeff Field, formerly of IDbyDNA, as Chief Commercial Officer. Field will work closely with the Clear Dx and Clear Safety product teams on executing against ambitious product roadmaps, including scaling the platform to accommodate new customer needs, as well as continued expansion into international markets.

With over two decades of experience in the healthcare space, Field has worked across both start-ups and multinational corporations, including pharmaceutical leaders Merck and AstraZeneca. During his tenure as Vice President in Oncology at Foundation Medicine, Field led the commercialization of NGS sequencing, enabling novel applications of the technology and fostering new customer relationships. Built through his most recent roles, Field has a strong background in genetic disorders and infectious disease.

“Jeff bridges the gap between science and business in a way that allows him to get into the customer’s shoes, while also working shoulder-to-shoulder with the scientists. It’s a rare, interdisciplinary skillset,” said Sasan Amini, CEO of Clear Labs. “Particularly as we begin to roll-out Clear Dx to key strategic partners, we’re thrilled to have Jeff onboard and excited to see how he supports the expansion of our NGS platform to a market that we know will benefit greatly from the depth and precision of the technology.”

An experienced operator in the NGS and diagnostics industry, Field will oversee the ongoing commercialization of Clear Safety and Clear Dx nationally and internationally, including the marketing and sale of both products to partners in food safety and in healthcare.

“Throughout my career, I’ve been dedicated to applying NGS to areas of high-impact and high-need. Due to the complexity of the technology, as well as its cost, this wasn’t always easy. That’s what impressed me most about Clear Labs — they make it look easy while also delivering incredible results for their customers,” said Field. “Clear Labs has realized the promise of NGS technology by making it affordable, effective, and fast. It is an honor to be joining the team that is enabling the deployment of NGS at scale and opening up this technology to important applications across food safety and clinical diagnostics.”

Clear Labs’ mission is to democratize industrial and clinical diagnostics by introducing the very first intelligent and turn-key solution for screening pathogens. The company’s flagship product is the only fully-automated and intelligent NGS platform purpose-built for pathogen diagnostics. Through this platform, Clear Labs is ushering in a new era of descriptive diagnostic technologies by advancing seamless DNA sequencing, bioinformatics, and robotics. This proprietary system enables comprehensive analysis of pathogens through genomic characterization with greater accuracy, at a cost comparable to qPCR.

This summer, the company also announced that it had raised $21M to leverage the company’s underlying NGS technology in the clinical market, allowing them to enhance the availability and quality of COVID-19 diagnostic tests.

To learn more about Clear Labs, please visit: http://www.clearlabs.com/.

About Clear Labs

Clear Labs is the creator of the only automated and intelligent diagnostic NGS platform. We help our customers capitalize on a new era of technology by seamlessly integrating DNA sequencing, bioinformatics and robotics. The result democratizes genomics within settings never before possible.

With these capabilities, Clear Labs’ has become a prominent and trusted partner safeguarding the global food supply and enhancing preventative food safety management systems. Now, building further upon the award-winning fully automated system, we are leveraging our novel genomics platform for deep SARS-CoV-2 characterizing diagnostics.

The world’s largest brands and organizations have implemented and are already realizing the advantages of the Clear Labs’ system.

To learn more, please visit: http://www.clearlabs.com/.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Shannia Coley
JDI
443.471.6830
Email >
Visit website